利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

38 条记录 (耗时 0.022 秒)

    COMPOSITIONS AND METHODS FOR TISSUE ENGINEERING AND CELL BASED THERAPIES
    1.
    发明申请
    COMPOSITIONS AND METHODS FOR TISSUE ENGINEERING AND CELL BASED THERAPIES 审中-公开
    组织工程和细胞治疗的组合物和方法

    公开(公告)号：WO2012129073A2

    公开(公告)日：2012-09-27

    申请号：PCT/US2012029369

    申请日：2012-03-16

    申请人： UNIV VIRGINIA PATENT FOUND ,  BOTCHWEY III EDWARD A ,  LAUGHLIN MARY J ,  LYNCH KEVIN R ,  DAS ANUSUYA ,  AWOJOODU ANTHONY

    发明人： BOTCHWEY III EDWARD A ,  LAUGHLIN MARY J ,  LYNCH KEVIN R ,  DAS ANUSUYA ,  AWOJOODU ANTHONY

    IPC分类号： A61K31/13 ,  A61K31/137 ,  A61K31/4168 ,  A61P17/00 ,  A61P17/02

    CPC分类号： A61K31/495 ,  A61K31/135 ,  A61K31/137 ,  A61K31/395 ,  A61K31/4164 ,  A61K31/66 ,  A61K45/06 ,  A61K2300/00

    摘要： The present application discloses strategies to recruit and mobilize stem cells using S1P receptor selective agonists and antagonists as wells as regulators of chemokine receptors. In an in vivo ischemic model, S1P1/S1P3 activation with FTY720 impeded inflammatory cell infiltration and recruited endothelial progenitor cells (EPCs) with the potential to increase microvascular remodeling. S1P3 expression on marrow-derived cells was essential for this remodeling. Concurrent systemic S1P3 and CXCR4 antagonism mobilized hematopoietic stem cells (HSCs) with the ability to engraft and repopulate blood cells. Pre-treatment of donor HSCs with FTY720 increased homing toward SDF-1 and improved engraftment in marrow. FTY720-coated bone allografts coupled with systemic administration of VPC01091 enhanced bone allograft integration and new bone formation in bone defects. MSCs pre-treated with FTY720 exhibited increased migration toward SDF-1, a CXCR4+ ligand. The results show that S1P is a very powerful role player in pharmacological marrow-derived stem cell mobilization and recruitment.

    摘要翻译： 本申请公开了使用S1P受体选择性激动剂和拮抗剂作为趋化因子受体的调节剂募集和动员干细胞的策略。 在体内缺血模型中，具有FTY720的S1P1 / S1P3激活阻碍炎性细胞浸润并引起具有增加微血管重塑潜力的内皮祖细胞（EPCs）。 骨髓来源的细胞上的S1P3表达对于这种重塑是必不可少的。 并发系统性S1P3和CXCR4拮抗剂动员造血干细胞（HSCs），具有移植和再填充血细胞的能力。 FTY720对供体HSC的预处理增加了对SDF-1的归巢，改善了骨髓移植。 FTY720包被的骨同种异体移植物与全身施用的VPC01091相结合，增强骨同种异体移植物整合和骨缺损中的新骨形成。 用FTY720预处理的MSC表现出向SDF-1（CXCR4 +配体）的迁移增加。 结果表明，S1P在药理学骨髓干细胞动员和招募中是非常有力的角色。

    ORALLY AVAILABLE SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS AND ANTAGONISTS
    5.
    发明申请
    ORALLY AVAILABLE SPHINGOSINE 1-PHOSPHATE RECEPTOR AGONISTS AND ANTAGONISTS 审中-公开

    公开(公告)号：WO2005041899A3

    公开(公告)日：2006-11-02

    申请号：PCT/US2004036563

    申请日：2004-11-03

    申请人： UNIV VIRGINIA ,  LYNCH KEVIN R ,  MACDONALD TIMOTHY L

    发明人： LYNCH KEVIN R ,  MACDONALD TIMOTHY L

    IPC分类号： A61K31/4164 ,  A61K20060101 ,  A61K31/4196 ,  A61K31/426 ,  A61K31/433 ,  C07D231/10 ,  C07D233/61 ,  C07D263/48 ,  C07D273/02 ,  C07D277/28 ,  C07D295/18 ,  C07D307/38 ,  C07F9/6506

    CPC分类号： C07F9/65062

    摘要： The present invention relates to S1P analogs that have activity as S1Preceptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. The compounds have the general structure (I) wherein R 11 is C 5 -C 18 alkyl or C 5 -C 18 alkenyl; Q is selected from the group consisting of C 3 -C 6 optionally substituted cycloalkyl, C 3 -C 6 optionally substituted heterocyclic, C 3 -C 6 optionally substituted aryl C 3 -C 6 optionally substituted heteroaryl and; R 2 is selected from the group consisting of H, C 1 -C 4 alkyl, (C 1 -C 4 alkyl)OH and (C 1 -C 4 alkyl)NH 2 ; R 23 is H or C 1 -C 4 alkyl, and R 15 is a phosphonate ester or a phosphate ester or a pharmaceutically acceptable salt or tautomer thereof.

    摘要翻译： 本发明涉及具有作为S1Preceptor调节剂的活性的S1P类似物以及这些化合物用于治疗与不适当S1P受体活性相关的疾病的用途。 化合物具有通式（I），其中R 11是C 5 -C 18烷基或C 5 -C 15烷基， -C 18链烯基; Q选自C 3 -C 6任选取代的环烷基，C 3 -C 6亚烷基，C 3 -C 6 - 任选取代的杂环基，C 3 -C 6任选取代的芳基C 3 -C 6 -C 6任选取代的杂芳基和; R 2选自H，C 1 -C 4烷基，（C 1〜 C 4烷基）OH和（C 1 -C 4烷基）NH 2; R 23是H或C 1 -C 4烷基，R 15是膦酸酯或磷酸酯 酯或其药学上可接受的盐或互变异构体。

    THE HUMAN PSYCHOSINE RECEPTOR
    7.
    发明申请
    THE HUMAN PSYCHOSINE RECEPTOR 审中-公开
    人类心脏受体

    公开(公告)号：WO02077153A2

    公开(公告)日：2002-10-03

    申请号：PCT/US0143369

    申请日：2001-11-20

    申请人： UNIV VIRGINIA ,  LYNCH KEVIN R ,  IM DONG SOON

    发明人： LYNCH KEVIN R ,  IM DONG SOON

    IPC分类号： C07K14/705 ,  C12N

    CPC分类号： C07K14/705

    摘要： The present invention is directed to the psychosine (galactosylsphingosine) receptor (named TDAG8), antibodies that specifically bind to that receptor, and the use of the receptor to identify agonists or antagonists of TDAG8 receptor activity.

    摘要翻译： 本发明涉及精神病（半乳糖基鞘氨醇）受体（称为TDAG8），与该受体特异性结合的抗体，以及该受体用于鉴定TDAG8受体活性的激动剂或拮抗剂的用途。